These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34349062)

  • 1. [Performing integrative transcriptomic and chemical screening to identify patient-specific vulnerabilities in poor-prognosis acute myeloid leukemia].
    Hashimoto M; Ishikawa F
    Rinsho Ketsueki; 2021; 62(7):774-780. PubMed ID: 34349062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
    Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
    Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
    Kiyoi H; Kawashima N; Ishikawa Y
    Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Vulnerabilities in
    Uras IZ; Maurer B; Nebenfuehr S; Zojer M; Valent P; Sexl V
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.
    Grunwald MR; Levis MJ
    Semin Hematol; 2015 Jul; 52(3):193-9. PubMed ID: 26111466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [FLT3 inhibitors for acute myeloid leukemia].
    Kiyoi H
    Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition.
    Zhao XY; Zhang RR; Ye Q; Qiu F; Xu HY; Wei FG; Zhang H
    Curr Med Sci; 2020 Oct; 40(5):810-816. PubMed ID: 33123895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
    Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation.
    Heng H; Zhi Y; Yuan H; Wang Z; Li H; Wang S; Tian J; Liu H; Chen Y; Lu T; Ran T; Lu S
    Eur J Med Chem; 2019 Feb; 163():195-206. PubMed ID: 30508668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
    Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
    Wang ES
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.